What is the prevalence of Castleman disease?

Castleman disease is a rare group of lymphoproliferative disorders with an estimated prevalence of approximately 16 to 21 cases per million people in the United States. Because it is frequently underdiagnosed or misdiagnosed, these figures are considered estimates, and the true global prevalence of Castleman disease remains difficult to determine with absolute precision.

Is Castleman disease considered a rare condition?

Yes, Castleman disease is classified as a rare disease. It presents in two primary forms: unicentric (affecting a single lymph node region) and multicentric (affecting multiple regions). While the unicentric form is more common, the multicentric form is more aggressive and systemic. Data from the Castleman Disease Collaborative Network and NIH GARD emphasize that because symptoms often mimic lymphoma or autoimmune disorders, many patients remain undiagnosed for years, complicating global prevalence tracking.

How does Castleman disease vary by age and gender?

Castleman disease can affect individuals of any age, though the average age of onset varies by type. Unicentric Castleman disease typically presents in younger adults (median age around 35), while multicentric Castleman disease often appears in older adults (median age around 50-60). There is no significant gender disparity, as both males and females are affected with equal frequency across various populations.

What are the challenges in identifying exact prevalence?

Accurately mapping the prevalence of Castleman disease is hindered by several factors:

• Diagnostic Complexity: The disease mimics common infections and malignancies, leading to frequent misdiagnosis.


• Lack of Centralized Registries: Many countries do not track rare disorders like Castleman disease in a standardized national database.


• Pathological Variability: Distinguishing between idiopathic multicentric, HHV-8 associated, and unicentric forms requires specialized tissue biopsy analysis, which may not be available in all clinical settings.

Our community at DiseaseMaps.org currently includes 59 people with Castleman disease who have shared their experiences, providing a vital real-world perspective that complements clinical data by highlighting the patient journey from symptom onset to definitive diagnosis.

Next steps

• Consult with a hematologist or oncologist who specializes in lymphoproliferative disorders.


• Request a pathology review by an expert center if your diagnosis is unclear.


• Join the DiseaseMaps.org community to connect with others sharing their experience with Castleman disease.


• Explore resources from the Castleman Disease Collaborative Network (CDCN) for the latest clinical trial information.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Castleman disease overview.


• Orphanet: Rare disease database entry for Castleman disease (ORPHA:139).


• Castleman Disease Collaborative Network (CDCN): Clinical statistics and patient resources.


• OMIM (Online Mendelian Inheritance in Man): Clinical synopsis for Castleman disease.